The MonolixSuite comes with an API for R that allows to use Monolix and PKanalix from R, such that all you can do with the interface...
LD Micro 12th Annual Main Event Investor Conference
Our mission is to improve the productivity of science-based research & development enterprises by delivering innovative modeling and simulation software and insightful consulting services
Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists
Bosentan, clazosentan, and tezosentan are three small-molecule endothelin receptor antagonists (ERAs), displacing endothelin-1 (ET-1) from its binding site.
Pharmacokinetics of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Mice: Potential Enterohepatic Circulation and Target-Mediated Disposition
To evaluate the pharmacokinetics (PK) of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in mice after IV and oral administration and to develop mechanistic PK models to assess the potential...
Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity
Inhibition of aldose reductase (AR), the first enzyme of the polyol pathway, is a promising approach in treatment of diabetic complications.
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs ( Part 2 – Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies’ Input on Bioanalysis, Biomarkers and Immunogenicity)
The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place in New Orleans, LA on 1-5 April 2019 with an attendance of over 1000 representatives from...
In vitro–In vivo Relationship and Bioequivalence Prediction for Modified-Release Capsules Based on a PBPK Absorption Model
A physiologically based pharmacokinetic (PBPK) absorption model was developed in GastroPlus™ based on data on intravenous, immediate-release (IR), and modified-release (MR) drug products.thought
Population pharmacokinetic modeling and simulation of fremanezumab in healhy subjects and patients with migraine
Fremanezumab is a fully humanized IgG2 Δa/κ monoclonal antibody specific for calcitonin gene-related peptide developed and approved for the preventive treatment of migraine in adults.
Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin
To characterize the population pharmacokinetics (PK) and pharmacodynamics (PD) of the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin in healthy...
QSP/QST Modeling Support for NASH Drug Development
Quantitative Systems Pharmacology (QSP) Supports Clinical Development by Emphasizing Mechanistic Understanding of Pathophysiology and Treatment
Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
Fremanezumab is a fully humanized IgG2 Δa/κ monoclonal antibody specific for calcitonin gene-related peptide developed and approved for the preventive treatment of migraine in adults.
Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor
New Structure and Tautomer Handling Routines Aim to Improve Data Integrity in Drug Discovery
Benchmark 8th Annual Discovery Conference
Our mission is to improve the productivity of science-based research & development enterprises by delivering innovative modeling and simulation software and insightful consulting services
Relationship between the effects of food on the pharmacokinetics of oral antineoplastic drugs and their physicochemical properties
Food is known to affect drug absorption by delaying gastric emptying time, altering gastrointestinal pH, stimulating bile flow, increasing splanchnic blood flow, or physically interacting with drugs.
Drug-likeness of linear pentamidine analogues and their impact on the hERG K+ channel – correlation with structural features
This work presents drug-likeness and the cardiotoxicity profiles of six potent pentamidine analogs 1–6 and three new compounds 7–9 as chemotherapeutics for therapy of Pneumocystis jiroveci pneumonia.
Population pharmacokinetic modeling and simulation of fremanezumab in healthy subjects and patients with migraine
Fremanezumab is a fully humanized IgG2 Δa/κ monoclonal antibody specific for calcitonin gene-related peptide developed and approved for the
In Silico Molecular Docking Study of Delafloxacin against 4MQT for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Infection occurring in the skin and its associated soft tissues such as loose connective tissue and mucous membranes is known as...
Learning in silico Reactant and Bond-of-Metabolism Predictors for Human Cytochrome P450 Enzymes
Human beings are exposed to many chemicals through their routine interactions with the environment, such as food/drug consumption, household or...
Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML
Quizartinib is a once-daily, oral, highly potent and selective FLT3 inhibitor that has shown clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3 internal tandem duplications in...
A novel series of chlorinated plastoquinone analogs: Design, synthesis, and evaluation of anticancer activity
Herein, we report the synthesis and cytotoxic effects of novel chlorinated plastoquinone analogs (ABQ1–17) against different leukemic cells.